Amodio and colleagues found that KRASG12C-mutant CRC cell lines displayed higher basal RTK activation, especially EGFR, than NSCLC cell lines; they then revealed that the reactivation of EGFR reversed the efficacy of AMG 510 in CRC. Here, EGFR is linked to colorectal carcinoma.